Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 8/20 | 0.54 |
| ▸ | RAB9A | P51151 | 7/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | TP53 | P04637 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL824375 | 0.77 | NPC1 (0.69) | NPC1RAB9AMAPTALDH1A1TP53 | |
| SCHEMBL29531707 | 0.77 | NPC1 (0.69) | NPC1RAB9AMAPTALDH1A1TP53 | |
| SCHEMBL6445389 | 0.71 | NPC1 (0.54) | NPC1RAB9AMAPTALDH1A1TP53 | |
| SCHEMBL6445384 | 0.71 | NPC1 (0.54) | NPC1RAB9AMAPTALDH1A1TP53 | |
| SCHEMBL129661 | 0.71 | MAPT (0.59) | NPC1RAB9AMAPTALDH1A1TP53 | |
| SCHEMBL474946 | 0.71 | NPC1 (0.54) | NPC1RAB9AMAPTALDH1A1TP53 | |
| SCHEMBL10045305 | 0.71 | NPC1 (0.54) | NPC1RAB9AMAPTALDH1A1TP53 | |
| SCHEMBL9542349 | 0.71 | NPC1 (0.54) | NPC1RAB9AMAPTALDH1A1TP53 | |
| SCHEMBL1280187 | 0.71 | NPC1 (0.54) | NPC1RAB9AMAPTALDH1A1TP53 | |
| SCHEMBL22190326 | 0.71 | NPC1 (0.54) | NPC1RAB9AMAPTALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109476674-A | Coumarin compound and its purposes as fluorescent marker | 伊鲁米纳剑桥有限公司 | 2019-03-15 | — | — | CN | disclosed |
| CN-101506201-B | Novel heteroaryl-substituted benzazoles derivatives | ASTRAZENECA AB | 2012-03-14 | — | — | CN | disclosed |
| CN-101506201-A | Novel heteroaryl substituted benzoxazoles | ASTRAZENECA AB (SE) | 2009-08-12 | — | — | CN | disclosed |
| WO-2002004440-A9 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED INDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2005-11-03 | — | — | WO | disclosed |
| EP-1299382-B1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED INDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2005-09-21 | — | — | EP | disclosed |
| EP-1299382-A4 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED INDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2004-02-11 | — | — | EP | disclosed |
| US-6573262-B2 | Compounds for treating mammals infected with HIV virus | BRISTOL-MYERS SQIBB COMPANY | 2003-06-03 | — | — | US | disclosed |
| US-20030069245-A1 | Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2003-04-10 | — | — | US | disclosed |
| EP-1299382-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED INDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-04-09 | — | — | EP | disclosed |
| WO-2002004440-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED INDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069245-A1 | Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives | IDO1, IDO2, ITPA | NPC1 2613/4885RAB9A 4168/4885MAPT 2659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.